SPAK inhibitor ZT‐1a attenuates reactive astrogliosis and oligodendrocyte degeneration in a mouse model of vascular dementia
Mohammad Iqbal H. Bhuiyan,Khadija Habib,Tipu Sultan,Fenghua Chen,Israt Jahan,Zhongfang Weng,Shamim Rahman,Rabia Islam,Lesley M. Foley,T. Kevin Hitchens,Xianming Deng,Scott W. Canna,Dandan Sun,Guodong Cao,Md Tipu Sultan,Md Shamim Rahman
DOI: https://doi.org/10.1111/cns.14654
2024-03-05
CNS Neuroscience & Therapeutics
Abstract:Cerebral hypoperfusion‐induced increased activity of the SPAK‐NKCC1 pathway contributes to reactive astrogliosis and subsequent demyelination and cognitive impairment in a mouse model of vascular dementia. SPAk inhibitor ZT‐1 improved cognitive impairment by preventing reactive astrogliosis and demyelination. Therefore, SPAK‐NKCC1 can be a potential therapeutic target for treating vascular dementia. Background Astrogliosis and white matter lesions (WML) are key characteristics of vascular contributions to cognitive impairment and dementia (VCID). However, the molecular mechanisms underlying VCID remain poorly understood. Stimulation of Na‐K‐Cl cotransport 1 (NKCC1) and its upstream kinases WNK (with no lysine) and SPAK (the STE20/SPS1‐related proline/alanine‐rich kinase) play a role in astrocytic intracellular Na+ overload, hypertrophy, and swelling. Therefore, in this study, we assessed the effect of SPAK inhibitor ZT‐1a on pathogenesis and cognitive function in a mouse model of VCID induced by bilateral carotid artery stenosis (BCAS). Methods Following sham or BCAS surgery, mice were randomly assigned to receive either vehicle (DMSO) or SPAK inhibitor ZT‐1a treatment regimen (days 14–35 post‐surgery). Mice were then evaluated for cognitive functions by Morris water maze, WML by ex vivo MRI‐DTI analysis, and astrogliosis/demyelination by immunofluorescence and immunoblotting. Results Compared to sham control mice, BCAS‐Veh mice exhibited chronic cerebral hypoperfusion and memory impairments, accompanied by significant MRI DTI‐detected WML and oligodendrocyte (OL) death. Increased activation of WNK‐SPAK‐NKCC1‐signaling proteins was detected in white matter tissues and in C3d+GFAP+ cytotoxic astrocytes but not in S100A10+GFAP+ homeostatic astrocytes in BCAS‐Veh mice. In contrast, ZT‐1a‐treated BCAS mice displayed reduced expression and phosphorylation of NKCC1, decreased astrogliosis, OL death, and WML, along with improved memory functions. Conclusion BCAS‐induced upregulation of WNK‐SPAK‐NKCC1 signaling contributes to white matter‐reactive astrogliosis, OL death, and memory impairment. Pharmacological inhibition of the SPAK activity has therapeutic potential for alleviating pathogenesis and memory impairment in VCID.
pharmacology & pharmacy,neurosciences